L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
Management of cutaneous toxicity induced by epidermal growth factor receptor inhibitors (EGFR-I) in squamous cell carcinomas of the head and neck, colorectal or lung cancer
- 5min
- May. 2022
- Supported by
EGFR-I frequently induce skin or appendage toxicities that may impact patient’s quality of life and lead to reduction in the dose or event the discontinuation of the anti-tumor treatment. Wound healing products can be used to manage cutaneous toxicities in association with pharmacological measures.